New vaccine combo aims to tackle persistent HPV infection

NCT ID NCT03913117

NEW Recruiting now Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen May 16, 2026 · Last updated May 16, 2026

Summary

This early-stage trial tests whether two vaccines, given as a shot, are safe for people with a long-lasting HPV16 infection that has caused mild cervical cell changes. About 30 adults will receive the vaccines to find the best dose and check for side effects. The goal is to help the immune system fight the virus and prevent the condition from getting worse.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASC-US are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Johns Hopkins University
RECRUITING

Baltimore, Maryland, 21231, United States

Contact Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••
UAB | The University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35249, United States

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ASC-US LSIL